BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 30254634)

  • 1. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
    Schmiedel D; Mandelboim O
    Front Immunol; 2018; 9():2040. PubMed ID: 30254634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NKG2D axis: an emerging target in cancer immunotherapy.
    Lazarova M; Steinle A
    Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
    Lazarova M; Wels WS; Steinle A
    Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells.
    Cho H; Son WC; Lee YS; Youn EJ; Kang CD; Park YS; Bae J
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34203519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.
    El-Gazzar A; Groh V; Spies T
    J Immunol; 2013 Aug; 191(4):1509-15. PubMed ID: 23913973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NKG2D in tumor surveillance.
    Hayakawa Y
    Expert Opin Ther Targets; 2012 Jun; 16(6):587-99. PubMed ID: 22530569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention.
    Molfetta R; Zingoni A; Santoni A; Paolini R
    Front Immunol; 2019; 10():2557. PubMed ID: 31736972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in NKG2D ligand recognition and responses by NK cells.
    Le Bert N; Gasser S
    Immunol Cell Biol; 2014 Mar; 92(3):230-6. PubMed ID: 24445601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
    Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
    Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.
    Paschen A; Baingo J; Schadendorf D
    Eur J Cell Biol; 2014; 93(1-2):49-54. PubMed ID: 24629838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of NKG2D-Mediated Tumor Immunity by TGF-β.
    Lazarova M; Steinle A
    Front Immunol; 2019; 10():2689. PubMed ID: 31803194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKG2D signaling in cancer immunosurveillance.
    López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S
    Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKG2D ligands as therapeutic targets.
    Spear P; Wu MR; Sentman ML; Sentman CL
    Cancer Immun; 2013; 13():8. PubMed ID: 23833565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
    Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
    J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.